Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients
A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients

NCT07477756

CompletedN/A

Sponsor: Novartis Pharmaceuticals

Conditions: Prostate Cancer

Countries: United States

The aim of this study was to assess the characteristics, treatment patterns, and clinical outcomes among metastatic castration-resistant prostate cancer (mCRPC) patients in the United States (US) who were treated with lutetium-177 vipivotide tetraxetan (177Lu-PSMA-617) in the real-world setting.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion criteria:

* Evidence of 177Lu-PSMA-617 use on or after March 23, 2022
* Date of initiation of 177Lu-PSMA-617 available in the data
* Age ≥18 years at index

Exclusion criteria:

• None
Locations (1)
  • East Hanover, New Jersey, United States